Ghana's uphill battle to defeat Malaria

As Ghanascales up access to newly approvedmalaria vaccines—building on years of clinical trials that demonstrated promising protection for young children—the moment marks a major scientific and public‑health milestone in a country where malaria remains a leading cause of child illness and death. Yet this progress is unfolding against a tightening financial backdrop: the winding down of USAID support, which has long underpinned malaria surveillance, prevention campaigns, and trial infrastructure, threatens to slow vaccine rollout and strain health systems. Researchers and public‑health officials warn that without sustained donor investment to replace USAID funding, gains from the vaccine trials could be undermined by gaps in cold‑chain logistics, community outreach, and monitoring, leaving Ghana’s malaria fight at a pivotal but uncertain